Gant CM, et al. - This post-hoc analysis was carried out to identify the determinants of aldosterone and its relation to blood pressure in chronic kidney disease (CKD) patients. Researchers studied this during renin-angiotensin-aldosterone system inhibition (RAASi) to establish clinical relevance, as RAASi is the treatment of choice in CKD with albuminuria. Findings revealed that worse renal function was associated with a higher aldosterone, untreated and during RAASi with either ARB (losartan 100 mg/day), ACEi (ACE inhibition), or both, in CKD patients with a standardized regular sodium intake. In addition, data reported a relation between higher aldosterone and higher blood pressure, which could be treated with the combination of RAASi, HCT (hydrochlorothiazide 25 mg/day) and dietary sodium restriction.